Socinski MA - Search Results

1

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC. Stinchcombe TE, et al. Among authors: socinski ma. Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66. doi: 10.1007/s00280-007-0423-x. Epub 2007 Feb 7. Cancer Chemother Pharmacol. 2007. PMID: 17285317 Free PMC article. Clinical Trial.

2

High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.

Socinski MA, Shea TC. Socinski MA, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-45-S12-51. Semin Oncol. 1997. PMID: 9331121 Review.

3

Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.

Socinski MA, Clark JA, Halle J, Steagall A, Kaluzny B, Rosenman JG. Socinski MA, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-117-S12-122. Semin Oncol. 1997. PMID: 9331135 Clinical Trial.

4

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.

Socinski MA, Mudd PN Jr, Radomski KM, Steagall A, Lawrence P, Bernard S, Letrent SP, Gonzalez P, Brouwer KL. Socinski MA, et al. Anticancer Drugs. 1998 Aug;9(7):611-9. doi: 10.1097/00001813-199808000-00006. Anticancer Drugs. 1998. PMID: 9773805 Clinical Trial.

5

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

Socinski MA, Steagall A, Gillenwater H. Socinski MA, et al. Cancer Invest. 1999;17(3):181-8. doi: 10.3109/07357909909021419. Cancer Invest. 1999. PMID: 10099656 Clinical Trial.

6

Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.

Socinski MA. Socinski MA. Oncologist. 1999;4(5):408-16. Oncologist. 1999. PMID: 10551557 Free article.

7

Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.

Socinski MA, Langer CJ. Socinski MA, et al. Semin Oncol. 1999 Oct;26(5 Suppl 16):51-61; discussion 71-2. Semin Oncol. 1999. PMID: 10585009 Review.

8

Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.

Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Socinski MA, et al. Cancer. 2000 Aug 1;89(3):534-42. Cancer. 2000. PMID: 10931452 Clinical Trial.

9

Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.

Natale RB, Socinski M, Sandler A, Israel VP, Miller L. Natale RB, et al. Oncology (Williston Park). 2000 Jul;14(7 Suppl 5):29-34. Oncology (Williston Park). 2000. PMID: 10981288 Free article. Clinical Trial.

10

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB. Socinski MA, et al. J Clin Oncol. 2001 Feb 15;19(4):1078-87. doi: 10.1200/JCO.2001.19.4.1078. J Clin Oncol. 2001. PMID: 11181672 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters